# ChemPion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chempion

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.chempion.com.cn
- Total disclosed funding: $14M
- Latest round: Series C (Feb 4, 2026)
- Investors on record: 10

## About

Based in Beijing, China and founded in 2016, Beijing Huaguan Biotechnology Co., Ltd, trading as ChemPion, is a biotech company that focuses on building a pharmaceutical industrialization innovation platform. In 2019, the company launched the CMC platform for small molecule preparations in Zhengzhou Linkong Biomedical Park. It has set up 4 R&D centers in Beijing, Nanjing, Suzhou, and Chongqing, and is building a 100-mu GMP production base for green APIs in Fuyang, Anhui. In February 2026, ChemPion raised a series C funding from new investor Changzhou Qihang Synthetic Biology Venture Capital Fund, returning investors SoftBank China Capital, Shunxi Fund, SDIC Chuangyi, Changjiang Capital and other investors.

The company's main products include continuous flow and enzyme-catalyzed production technology platforms for APIs, pharmaceutical intermediates, APIs and intermediates, etc. APIs and intermediates include 2-(1-Methylcyclopropyl) acetic acid and 6-Bromonaphthalen-2-amine, etc. It also provides services such as drug CMC research and development, technology transfer, registration application, industrialization, etc.

The company's revenue is generated by providing continuous flow and enzyme-catalyzed production technology platforms for APIs, pharmaceutical intermediates, APIs and intermediates, etc.

The company will use the latest funding for new product development in the pharmaceutical and healthcare sectors, expansion of production bases, and the establishment of innovative cooperation platforms.

## Funding rounds

- Series C, Feb 4, 2026 — SB China Venture Capital, Shunxi Fund, SDIC Chuangyi, Changjiang Capital
- Series B, Dec 10, 2025 — SB China Venture Capital, Zhendong Health Industry Group Co. Ltd., Proya Cosmetics, Shunxi Fund, SDIC Chuangyi, Changjiang Capital, Qihang Capital
- Series B, Sep 27, 2022, $14M — Lotus Lake Capital, Shanghai Shengjing Jiacheng Venture Capital Management, Zhongguancun Science City Capital
- Angel, Jul 2, 2018 — Lotus Lake Capital

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Angel, Series B
- Shanghai Shengjing Jiacheng Venture Capital Management — Series B
- Zhongguancun Science City Capital (https://capitalatlas.ai/funds/zhongguancun-science-city-capital) — Series B
- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series B, Series C
- Zhendong Health Industry Group Co. Ltd. — Series B
- Proya Cosmetics — Series B
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series B, Series C
- SDIC Chuangyi (https://capitalatlas.ai/funds/sdic-chuangyi) — Series B, Series C
- Changjiang Capital (https://capitalatlas.ai/funds/changjiang-capital) — Series B, Series C
- Qihang Capital (https://capitalatlas.ai/funds/qihang-capital) — Series B